NetNoggin® releases results from “Utilization of Technology in Alzheimer’s Disease” research study

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

FREDERICK, Md., July 16, 2019 /PRNewswire/ — NetNoggin® released detailed results from a netnographic-qualitative research study, which investigated the utilization of technology in Alzheimer’s disease (including mild cognitive impairment [MCI]), presented at the Alzheimer’s Association International Conference® (AAIC) 2019 held in Los Angeles, California, July 14 – 18. NetNoggin® analyzed patient and caregiver conversations to determine which Intelligent Assistive Technologies (IATs) were being utilized, at what stage of progression, the application, and the user population to determine technology needs/gaps within the Alzheimer’s marketspace. Results from this research provide insights into IATs, pointing to new strategies for development and awareness.

Inspired by the consumer. (PRNewsfoto/NetNoggin)Inspired by the consumer. (PRNewsfoto/NetNoggin)

“Primary and secondary research have taken steps towards understanding technology within Alzheimer’s disease. However, our netnographic analysis has allowed us to understand not only what patients and caregivers are currently adopting, but also what they need, providing opportunities to improve patient and caregiver quality of life using technological solutions,” said Diana Conger, CEO of NetNoggin®.

Visit https://netnoggin.net/news to request a PDF of the research, “Utilization of Technology in Alzheimer’s Disease and MCI.”

NetNoggin® continues to participate in the Alzheimer’s disease space with their syndicated report, NetNog: #genesis® Alzheimer’s Disease (including MCI). This report captures insights from a large volume of rich contextual conversations, with raw and unbiased lexicon, occurring online. Patients and caregivers write in the present, and there is no bias related to recall, unlike traditional research (interviews or surveys). For more information on NetNog: #genesis® Alzheimer’s Disease (including MCI), visit https://netnoggin.net/disease-focused-research.

About NetNoggin®
NetNoggin®, a subsidiary of Conger Consulting, LLC, is a premier market research agency that specializes in pharmaceutical marketing. NetNoggin® utilizes netnography to analyze and provide context to Big Data. By leveraging 30+ years of experience, their proprietary process derives strategic consulting insights from Big Data to inform Foundational Marketing Tools (FMTs), strategies, and tactics. NetNoggin® has expertise in market research; commercial, market, and clinical development; and communications to provide reliable research, presentations, and workshops. NetNoggin® was established in 2011. The founder, Diana Conger, has been involved in bringing over 20 pharmaceutical products to market and has in-depth knowledge of over 50 disease-states.

NetNoggin® Media Relations
If you would like more information on this topic, please contact Megan Newcomer.
E-mail: megan.newcomer@netnoggin.net

View original content to download multimedia:http://www.prnewswire.com/news-releases/netnoggin-releases-results-from-utilization-of-technology-in-alzheimers-disease-research-study-300885405.html

SOURCE NetNoggin

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago